Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
